Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Shares in Alligator Energy (ASX:AGE) jumped sharply after the company announced key progress at its Samphire uranium project in South Australia, including the launch of a field recovery trial and advancing mining lease approvals, setting the stage for a bankable feasibility study targeted for early 2027.
Alibaba-backed Moonshot AI has unveiled an upgraded flagship model, Kimi K2.5, asserting superiority in video generation and agentic capabilities against leading U.S. models. The development coincides with Beijing's approval for major tech firms, including Alibaba, to import advanced Nvidia H200 AI chips, signaling a dual-track strategy in the intensifying global AI race.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Stockholders of CSG Systems International have overwhelmingly approved a slate of key proposals, including governance changes and merger-related actions, during a recent virtual Extraordinary General Meeting. The approvals pave the way for the company's next phase of strategic growth.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
London-based trading giant IG Group has completed its takeover of Australian cryptocurrency exchange Independent Reserve, following regulatory approval in Singapore. The move paves the way for the launch of regulated crypto services in key markets including Singapore, Australia, and the UAE by late 2026.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Nubank, the Latin American fintech leader, has secured conditional approval from the OCC for a U.S. national bank charter, setting an 18-month timeline to launch and challenging incumbent banks with its digital-first model.
Nvidia strengthens its pivotal role in global AI infrastructure through a multi-pronged strategy: securing H200 chip approvals for China, engaging in advanced funding talks with OpenAI, and expanding partnerships with CoreWeave and international research bodies.
Tencent Holdings has received regulatory approval to import Nvidia's advanced H200 AI chips, a significant move that enhances its competitive edge in cloud and AI services while navigating ongoing US technology restrictions.
Federal officials have issued provisional approval to relocate 30 beluga whales and four dolphins from the shuttered Ontario park to accredited U.S. aquariums, averting an immediate euthanasia threat pending final health and care plans.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
Shareholders of New Gold Inc. (TSX:NGD) and Coeur Mining, Inc. have given resounding approval to Coeur's plan to acquire all outstanding shares of New Gold. The vote clears a critical path for the merger, which now awaits final regulatory and court nods to create a significantly larger, diversified precious metals producer with enhanced scale and exploration prospects across North America.
Despite a challenging housing market, Five Point Holdings (NYSE:FPH) reported record annual net income for 2025, driven by strategic land sales and the integration of its Hearthstone platform. The company navigated economic uncertainty with disciplined pricing and secured major entitlement approvals to fuel its long-term pipeline.
The medical device developer Beta Bionics has received a warning letter from the U.S. Food and Drug Administration, a regulatory action stemming from a facility inspection last summer. The company maintains the letter will not disrupt its operations, manufacturing, or the planned launch of its new insulin patch pump.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
